An interventional study of Alvogyl Dressing and Platelet-Rich Fibrin (PRF) in Alveolar Osteitis, sponsored by CMH Lahore Medical College and Institute of Dentistry. Completed at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by CMH Lahore Medical College and Institute of Dentistry · Not applicable, Interventional, and Treatment
Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Alvogyl is a commonly used dressing for managing dry socket and can provide rapid pain relief. Platelet-rich fibrin (PRF) is a preparation made from the patient's own blood that contains platelets, white blood cells, fibrin, and growth factors that may promote tissue repair and wound healing.
This randomized controlled clinical trial will compare Alvogyl and platelet-rich fibrin in patients diagnosed with alveolar osteitis following third molar extraction. A total of 102 eligible adult participants will be randomly assigned to receive either Alvogyl or PRF as treatment for the affected extraction socket.
The study will compare the healing outcomes of the two treatments by assessing pain intensity and the number of exposed socket walls during follow-up. Pain will be assessed using a visual analogue scale, while socket healing will be evaluated clinically by recording the number of exposed socket walls.
The study aims to determine whether PRF provides better healing outcomes than conventional Alvogyl treatment for alveolar osteitis. The findings may help clinicians select an effective treatment approach for reducing pain and promoting healing in patients with dry socket.
Alveolar osteitis, commonly referred to as dry socket, is a frequent painful complication following tooth extraction. It is characterized by persistent or increasing postoperative pain, typically developing within the first few days after extraction, and may be associated with an empty extraction socket, foul odour, and delayed local healing. The condition can substantially affect patient comfort and quality of life and may require additional clinical management.
Several treatment approaches have been used for alveolar osteitis, including socket irrigation, local dressings, analgesics, antibiotics in selected circumstances, and regenerative materials. Alvogyl is a commonly used intra-alveolar dressing that is intended to provide symptomatic relief and protect the affected socket. Although it can provide rapid pain relief, concerns have been raised regarding its potential effect on the rate of socket healing.
Platelet-rich fibrin (PRF) is an autologous platelet concentrate prepared from the patient's own venous blood without the use of anticoagulants. During centrifugation, a fibrin-rich matrix containing platelets and leukocytes is formed. This matrix serves as a scaffold for tissue repair and provides a sustained release of biologically active mediators, including growth factors involved in angiogenesis, cellular proliferation, and wound healing. PRF has therefore been investigated as a regenerative treatment for extraction socket healing and alveolar osteitis.
Previous clinical studies comparing Alvogyl and PRF have reported differences in pain relief and socket healing. Some evidence suggests that Alvogyl may provide more rapid symptomatic pain relief, whereas PRF may promote more favourable or faster clinical healing. However, variation in study findings and treatment protocols indicates a need for further controlled clinical investigation.
This study is designed as a randomized, double-blind, controlled clinical trial comparing Alvogyl with PRF for the treatment of alveolar osteitis following third molar extraction. Eligible participants will be randomly allocated to receive either Alvogyl or an autologous PRF membrane. Both treatment groups will undergo standardized socket irrigation and debridement before placement of the assigned treatment. The extraction socket will subsequently be secured using sutures.
The primary purpose of the study is to compare healing outcomes between the two treatment approaches. Clinical assessment will include evaluation of pain intensity using a 0-10 visual analogue scale and assessment of the number of exposed socket walls. Participants will be assessed during postoperative follow-up to determine changes in pain and socket healing.
A total of 102 adult participants will be enrolled, with 51 participants allocated to each treatment group. The study will be conducted in the Department of Oral and Maxillofacial Surgery at CMH Medical College and Institute of Dentistry, Lahore. All procedures will be performed by the same surgical team under the supervision of an experienced consultant oral surgeon.
The study will provide comparative clinical evidence regarding the use of conventional Alvogyl dressing and autologous PRF for management of alveolar osteitis. The findings may contribute to evidence-based selection of treatment modalities aimed at reducing postoperative pain and improving healing of affected extraction sockets.
46 studies on the registry are indexed under Dry Socket; 10 are open to participants now.
This study's enrollment of 102 is above the median of 60 across 41 interventional studies indexed under Dry Socket.
Browse Dry Socket studies →CMH Lahore Medical College and Institute of Dentistry is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with alveolar osteitis will receive standard socket irrigation with warm saline and debridement, followed by placement of Alvogyl into the extraction socket. The socket will be secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
Procedure: Alvogyl Dressing
Participants diagnosed with alveolar osteitis will receive autologous platelet-rich fibrin (PRF). Ten millilitres of venous blood will be collected and centrifuged without anticoagulant to prepare a PRF membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
Biological: Platelet-Rich Fibrin (PRF)
Alvogyl will be used as an intra-alveolar dressing for the treatment of alveolar osteitis. Following gentle irrigation of the extraction socket with warm saline and debridement, Alvogyl will be placed into the socket. The socket will then be secured with 3-0 silk sutures using a figure-of-eight technique to maintain the dressing in position. No topical or systemic antibiotics will be administered.
Autologous platelet-rich fibrin will be prepared from 10 mL of the participant's venous blood collected into two 5-mL tubes without anticoagulant. The blood will be centrifuged at 3000 rpm for 10 minutes. The resulting PRF layer will be separated and compressed between sterile saline-moistened gauze to form a membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
Mean Pain Score
Pain intensity will be assessed using a 0-10 Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. The mean VAS pain score on postoperative Days 1 and 3 will be compared between the Alvogyl and platelet-rich fibrin groups.
Time frame: Postoperative Day 1 and 3
Mean Number of Socket Wall Exposures
The number of exposed socket walls will be assessed by clinical examination on postoperative Days 1 and 3. The mean number of socket wall exposures will be compared between the Alvogyl and platelet-rich fibrin groups to evaluate the healing status of the extraction socket.
Time frame: Days 1 and 3
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: P-prf
CMH Lahore Medical College and Institute of Dentistry